Investing.com - Truist Securities lowered its price target on Evolent Health (NYSE:EVH) shares to $6 from $10 while maintaining a Buy rating on the stock. The stock currently trades at $3.01, down 75% over the past year and 74% in the last six months.
The price target adjustment follows a post-quarterly call between Truist analyst Jailendra Singh and Evolent Health management. The discussion covered the company's fourth quarter 2025 results and its outlook for 2026.
The call also addressed cost trends and other topics related to the healthcare technology company's operations. Singh noted the firm's questions and the company's responses in the research note. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value of $4.15.
The analyst clarified that the responses provided were not verbatim quotes but were contextualized from the exchange with management. The discussion took place in a question-and-answer format.
Truist updated its price target based on the information gathered during the management call. The firm continues to rate Evolent Health shares as a Buy despite the reduced price target.
In other recent news, Evolent Health reported fourth-quarter results that exceeded expectations, with EBITDA surpassing estimates by 5.9% and 6% according to BMO Capital and KeyBanc, respectively. Despite the positive earnings performance, KeyBanc downgraded Evolent Health to Sector Weight from Overweight, citing leverage concerns following the company's 2026 guidance. Meanwhile, BMO Capital maintained its Outperform rating but lowered its price target to $3.50 from $7.00, focusing on the achievability of the company's 2026 guidance.
Additionally, Piper Sandler significantly reduced its price target for Evolent Health to $6.00 from $18.00, while maintaining an Overweight rating. The firm expressed concerns about anticipated enrollment declines in the Individual ACA Marketplace and Medicaid, which are expected to impact Evolent Health’s revenue over the next two years. Citizens also lowered its price target to $10.00 from $11.00, maintaining a Market Outperform rating, due to more conservative operating margin assumptions and potential erosion of ACA membership in 2026. These recent developments highlight the varied analyst perspectives on Evolent Health’s future performance and strategic challenges.
This article was generated with the support of AI and reviewed by an editor.